Clinical use of testosterone in hypogonadism and other conditions

Testosterone: Action, Deficiency, Substitution, Fourth Edition

Volumn , Issue , 2012, Pages 292-308

  Nieschlag, Eberhard ^a   Behre, Hermann M ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84896789364     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9781139003353.015     Document Type: Chapter

References (85)

1. Aaronson AJ, Morrissey RP, Nguyen CT, Willix R, Schwarz ER (2011)Update on the safety of testosterone therapy in cardiac disease. Expert Opin Drug Saf10:697-704
2. Adamopoulos DA, Nicopoulou S, Kapolla N, Vassipoulos P, aramertzanis M, Kontogeorgos L (1995) Endocrine effects of testosterone undecanoate as a supplementary treatment to menopausal gonadotropins or tamoxifen citrate in idiopathic oligozoospermia. Fertil Steril 64:818-824
3. Adamopoulos DA, Nicopoulou St, Kapolla N, Karamertzanis M, Andreou E (1997) The combination of testosterone undecanoate with tamoxifen citrate enhances the effects of each agent given independently on seminal parameters in men with idiopathic oligozoospermia. Fertil Steril 67:756-762
4. AkcamT, Bolu E, Merati AL, DurmusC, Gerek M, Ozkaptan Y (2004) Voice changes after androgen therapy for hypogonadotrophic hypogonadism. Laryngoscope 114:1587-1591
5. Albanese A, Stanhope R (1995) Predictive factors in the determination of final height in boys with constitutional delay of growth and puberty. J Pediatr 126:545-550
6. Albanese A, Kewley GD, Long A, Pearl KN, Robins DG, Stanhope R (1994) Oral treatment for constitutional delay of growth and puberty in boys: a randomized trial of an anabolic steroid or testosterone undecanoate. Arch DisChild71:315-317
7. Arrigo T, Crisafulli G, Salzano G, Zirilli G, De Luca F (2005) Highflow priapism in testosteronetreated boys with constitutional delay of growth and puberty may occur even when very low doses are used. J Endocrinol Invest 28:390-391
8. Attal P, Chanson P (2010) Endocrine aspects of obstructive sleep apnea.J Clin Endocrinol Metab95:483-495
9. Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319-325
10. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S (2010) Adverse events associated with testosterone administration. N Engl J Med363:109-222
11. Behre HM, Bohmeyer J, Nieschlag E (1994) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol40:341-349
12. Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E (1999a) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. EurJ Endocrinol140:414-419
13. Behre HM, von Eckardstein S, Kliesch S, Nieschlag E (1999b) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7-10 years. Clin Endocrinol 50:629-635
14. Bettendorf M, Heinrich UE, Schönberg DK, Grulich-Henn J (1997) Short-term, high dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature. EurJ Pediatr156:911-915
15. Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, Nielson C, Wu F, Tajar A, Labrie F, Vesper H, Zhang A, Ulloor J, Singh R, D’Agostino R, Vasan RS (2011) Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a communitybased sample of healthy nonobese young men in the Framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab96: 2430-2439
16. Bojesen A, Juul S, Gravholt CH (2003) Prenatal and postnatal prevalence of Klinefelter syndrome: a national registry study. J Clin EndocrinolMetab88:622-626
17. Bojesen A, Stockholm K, Juul S, Gravholt CH (2011) Socioeconomic trajectories affect mortality in Klinefelter syndrome. J ClinEndocrinol Metab96:2098-2104
18. Brabrand S, Fosså SD, Cvancarova M, Lehne G (2011) Androgen substitution with testosterone undecanoate in survivors of bilateral testicular cancer requires individually-adjusted injection intervals. BJU Int107:1080-1087
19. Brown D, Butler CGE, Kelnar CJH, Wu FCW (1995) A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth of small for age, prepubertal boys. Arch Dis Child73:141-145
20. Büchter D, Behre HM, Kliesch S, Nieschlag E (1998) Pulsatile GnRH or human chorionic gonadotropin human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. Eur J Endocrinol149:298-303
21. Burris AS, Banks SM, Carter CS, Davidson JM, Sherins RJ (1992) A long-term prospective study of the physiologic and behavioural effects of hormone replacement in untreated hypogondadal men. J Androl14:297-304
22. Calof OM Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (2005) Adverse events associated with testosterone replacement inmiddleaged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol SciMed Sci 60:1451-1457
23. Charny CW, Gordon JA (1978) Testosterone rebound therapy: a neglected modality. Fertil Steril 29:64-68
24. Comhaire F, Schoonjans F, Abelmassih R, Gordts S, Campo R, Dhont M, Milingos S, Gerris J (1995) Does treatment with testosterone undecanoate improve the in-vitro fertilizing capacity of spermatozoa in patients with idiopathic testicular failure? (Results of a double blind study). HumReprod10:2600-2602
25. Cunningham GR, Hirshkowitz M, Korenman SG, Karacan I (1990) Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin EndocrinolMetab70:792-797
26. Decker R, Pratsch C-J, Sippell WG (2002) Combined treatment with testosterone (T) and ethinylestradiol (EE2) in constitutionally tall boys: is treatment with T plus EE2 more effective in reducing final height in tall boys than T alone? J ClinEndocrinol Metab87:1634-1639
27. de Lange WE, Snoep MC, Doorenbos H (1979) The effect of short-term testosterone treatment in boys with delayed puberty. Acta Endocrinol 91:177-183
28. Depenbusch M, von Eckardstein S, Simoni M, Nieschlag E (2002) Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with hCG alone. EurJ Endocrinol147:617-624
29. de RondeW(2009) Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 24:425-428
30. deWaal WJ, Vreeburg JTM, Bekkering F, de Jong FH, de Muinck Keizer Schrama SMPF, Drop SLS, Weber RFA (1995) High dose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood? Clin Endocrinol 43:87-95
31. Drop SLS, de Waal WJ, de Muinck Keizer-Schrama SMPF (1998) Sex steroid treatment of constitutionally tall stature. Endocr Rev 19:540-558
32. Endres W, Shin YS, Rieth M, Block T, Schmiedt E, Knorr D (1987) Priapism in Fabry's disease during testosterone treatment. Klin Wschr 65:925
33. Franchi F, Luisi M, Kicovic PM (1978) Long-term study of oral testosterone undecanoate in hypogonadal males. Int J Androl 1:270-278
34. Gooren LJG (1994) A ten year safety study of the oral androgen testosterone undecanoate. J Androl 15:212-215
35. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, Schöfl C, Dörr M, Nauck M, Wallaschofski H (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J31:1494-1501
36. Hendriks AE, Boellaard WP, van Casteren NJ, Romijn JC, de Jong FH, Boot AM, Drop SL (2010) Fatherhood in tall men treated with high-dose sex steroids during adolescence. J Clin EndocrinolMetab95:5233-5240
37. Ichioka K, Utsunomiya N, Kohei N, Ueda N, Inoue K, Terai A (2006) Testosterone-induced priapism in Klinefelter syndrome. Urology 67:622.e17-622.e18
38. Ishii T, Sasaki G, Hasegawa T, Sato S, Matsuo N, Ogata T (2004) Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis. J Urol172:319-324
39. Jockenhövel F (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism48:590-596
40. Kamischke A, Nieschlag E (1999) Analysis of medical treatment of male infertility. Hum Reprod 14:1-23
41. Kühnert B, Byrne M, Simoni M, Köpcke W, Gerss J, Lemmnitz G, Nieschlag E (2005) Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: a multicentre trial. EurJ Endocrinol153:317-326
42. Lanfranco F, Kamischke A, Zitzmann M, Nieschlag E (2004) Klinefelter's syndrome. Lancet364:273-283
43. Laughlin GA, Barrett-Connor E, Bergstrom J (2008) Lowserumtestosterone and mortality in older men. J Clin Endocrinol Metab 93:68-75
44. Lee KK, Berman N, Alexander GM, Hull L, Swerdloff RS, Wang C (2003) A simple self-report diary for assessing psychosexual function in hypogonadal men. J Androl 25:688-698
45. Lemcke B, Zentgraf J, Behre HM, Kliesch S, Bramswig JH, Nieschlag E (1996) Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J ClinEndocrinol Metab81:296-301
46. Luboshitzky R, Aviv A, Hefetz A, Herer P, Shen-Orr Z, Lavie L, Lavie P (2002) Decreased pituitary-gonadal secretion inmen with obstructive sleep apnea.JClinEndocrinolMetab87:3394-3398
47. Luisi M, Franchi F (1980) Double-blind group comparative study of testosterone undecanoate and mesterolone in hypogonadal male patients. J Endocrinol Invest 3:305-308
48. McNicholas T, Ong T (2006) Review of Testim gel. Expert OpinPharmacother7:477-484
49. Morales A, Johnston B, Heaton JPW, Lundie M (1997) Testosterone supplementation for hypogonadal impotence: assessment of biochemical measures and therapeutic outcomes. J Urol 157:849-854
50. Nieschlag E, Cüppers HJ, Wiegelmann W, Wickings EJ (1976) Bioavailability and LH suppressing effect of different testosterone preparations in normal and hypogonadal men. HormRes7:148
51. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC (2004) Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 10:409-419
52. Nieschlag E, Behre HM, Nieschlag S (eds) (2010) Andrology. MaleReproductive Health andDysfunction, 3rd edn. Springer- Verlag, Berlin
53. Ohlsson C, Vandenput L (2009) The role of estrogens for male bone health. Eur J Endocrinol 160:883-889
54. Pedersen MF, Moller S, Krabbe S, Bennett P (1986) Fundamentalvoice frequency measured by electroglottography during continuous speech. A new exact secondary sex characteristic in boys in puberty. Int J Ped Otohinol 11:21-27
55. Pusch HH (1989) Oral treatment of oligozoospermia with testosteroneundecanoate: results of a doubleblind- placebo-controlled trial.Andrologia21:76-82
56. Raynaud JP, Augès M, Liorzou L, Turlier V, Lauze C (2009) Adhesiveness of a new testosteronein adhesive matrix patch after extreme conditions. Int J Pharmacol 375:28-32
57. Rogol AD (2005) New facets of androgen replacement therapy during childhood and adolescence. Expert Opin Pharmacother 6:1319-1336
58. Rolf C, von Eckardstein S, Koken U, Nieschlag E (2002) Testosteronesubstitution of hypogonadal men prevents the age-dependent increases in body mass index, bodyfat and leptin seen in healthy ageingmen: results of a cross-sectional study. Eur J Endocrinol146:505-511
59. Rosen RC, Araujo AB, Connor MK, Gerstenberger EP, Morgentaler A, Seftel AD, Miner MM, Shabsigh R (2011) The NERI Hypogonadism Screener: psychometric validation in male patients and controls. ClinEndocrinol74:248-256
60. Rosenfeld RG, Northcraft GB, Hintz RL (1982) A prospective, randomized study of testosterone treatment of constitutional delay of growth and development in male adolescents. Pediatrics69:681-687
61. Ruch W, Jenny P (1989) Priapismfollowing testosterone administration for delayed male puberty. Am J Med86:256
62. Schulte-Beerbühl M, Nieschlag E (1980) Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertil Steril33:201-203
63. Shabsigh R (1997) The effects of testosterone on the cavernous tissue and erectile function. World J Urol15:21-26
64. Shores MM, Matsumoto AM, Sloan KL, Kivlajam DR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660-1665
65. Skakkebaek NE, Bancroft J, Davidson DW, Warner P (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol 14:49-61
66. Snyder PJ (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J ClinEndocrinol Metab84:1966-1972
67. Snyder PJ, Lawrence DA (1980) Treatment of male hypogonadism with testosterone enanthate. J ClinEndocrinol Metab51:1335-1339
68. Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS (1982) Comparison of the kinetics of testosterone in eugonadal and hypogonadal men. Fertil Steril 37:425-430
69. Vermeulen A, Verdonck G (1992) Representatives of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab74:939-942
70. von Eckardstein S, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injection at extended intervals of 12 weeks: a phase II study. J Androl 23:419-425
71. Wang C, Alexander G, Berman N, Salehian B, Davidson T, McDonald V, Steiner B, Hull H, Callegari C, Swerdloff R (1996) Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. J ClinEndocrinol Metab81: 3578-3583
72. Wang C, Cunningham G, Dobs A (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin EndocrinolMetab89:2085-2098
73. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2008) Investigation, treatment and Monitoring of late onset hypogonadism in males. EurJ Endocrinol159:507-514
74. Wang C, Harnett M, Dobs AS, Swerdloff RS (2010) Pharmacokinetics and safety of long-acting testosterone undecanoate injections in Hypogonadal men: an 84-week phase III clinical trial. J Androl 31:457-465
75. Warne DW, Decosterd G, Okada H, Yano Y, Koide N, Howles CM (2009) A combined analysis of data to identify predictive factors for spermatogenesis in men with hypogonadotropic hypogonadism treated with recombinant human follicle-stimulating hormones and human chorionic gonadotropin. Fertil Steril92:594-604
76. Whitworth JA, Scoggins BA, Andrews J, Williamson PM, Brown MA (1992) Haemodynamic and metabolic effects of short term administration of synthetic sex steroids in humans. Clin ExpHypertens14:905-922
77. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol SciMed Sci58:618-625
78. World Health Organization, Task Force on the Diagnosis and Treatment of Infertility (1989) Mesterolone and idiopathic male infertility: a double-blind study. IntJ Androl12:254-264
79. World Health Organization, Nieschlag E, Wang C, Handelsman DJ, Swerdloff RS, Wu F, Einer-Jensen N, Waites G (1992) Guidelines for theUse of Androgens. WHO, Geneva
80. Zelissen PMJ, Stricker BHC (1988) Severe priapism as a complication of testosterone substitution therapy. Am J Med85:273
81. Zitzmann M, Nieschlag E (2001) Testosterone levels in healthy men and their relation to behavioural and physical characteristics: facts and constructs. Eur J Endocrinol144:183-197
82. Zitzmann M, Nieschlag E (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin EndocrinolMetab92:3844-3853
83. Zitzmann M, Rolf C, Brune M, Vieth V, Nieschlag E (2002) Monitoring bone density in hypogonadal men by quantitative phalangeal ultrasound. Bone31: 422-429
84. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E (2003) Prostate volume and growth in testosteronesubstituted hypogonadal men aredependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J ClinEndocrinol Metab88: 2049-2054
85. Zitzmann M, Faber S, Nieschlag E (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335-4343